Ligand Pharmaceuticals Incorporated announced on July 8, 2024, the company entered into the first amendment to the revolving credit facility, dated as of October 12, 2023, among the Company, certain of its subsidiaries, as Guarantors, the Lenders, and Citibank, N.A., as Administrative Agent, Swingline Lender and L/C Issuer. The Amendment amends the Credit Agreement to, among other things, increase the aggregate revolving credit facility amount from $75,000,000 to $125,000,000.